Early data on recruitment and enrollment from Photopharmics’ Phase 3 clinical trial of its light-based, at-home therapy device for Parkinson’s disease — a novel treatment called Celeste — highlight both the interest in, and feasibility of, fully remote studies done in a patient’s home, according to the company. Such home-based, decentralized…
P2B001, Pharma Two B’s investigational combination therapy of pramipexole and rasagiline, safely and effectively lessens symptoms in people with early-stage Parkinson’s disease, according to pooled data from Phase 2b and Phase 3 clinical trials. The combo treatment was also found to be as effective as titrated extended-release pramipexole…
Parkinson’s disease patients carrying the G2385R mutation in the LRRK2 gene, a known risk factor for the disease, show a slower worsening of tremors and less daytime sleepiness than those idiopathic Parkinson’s, whose disease has no identified cause, a study from China reports. The study also found that…
Axons, nerve cell projections that carry electrical signals from one cell to another, may look more like pearls on a string than the cylindrical tubes they are commonly believed to resemble, according to a study, which demonstrated that interfering with the formation of pearl-like structures impaired the transmission of electric…
A team of South Korean scientists has created technology that can measure brain activity in monkeys without the need for wires or batteries that would interfere with the normal instincts of the animal — an advancement, according to the scientists, that may ultimately aid in research into neurological conditions such…
Neuron-supporting cells called astrocytes produce regular pulses of gamma-aminobutyric acid (GABA), a chemical that suppresses excessive brain activity, that appear to help maintain the body’s circadian rhythms and consistent sleep-wake cycles. That’s according to a study in mice. The findings, if confirmed in humans, may “help us to better understand…
Serina Therapeutics has secured $10 million in new funding to support the development of its lead product, SER-252 (POZ-apomorphine), for treating advanced Parkinson’s disease. The goal, according to a company press release, is to advance the candidate therapy toward a Phase 1 clinical trial in patients by…
The Parkinson’s disease therapy entacapone may disrupt the balance of microbes in the gut by starving them of iron, a study in healthy human fecal samples suggests. Supplementing patients with iron could prevent entacapone’s gastrointestinal side effects, but more research is needed to fully understand how the medication affects…
A framework called the neuronal alpha-synuclein disease integrated staging system (NSD-ISS) to stage patients in the early stretch of Parkinson’s disease, or who have yet to manifest symptoms, can help predict how quickly they may progress to clinically meaningful milestones. In a study led by Tanya Simuni, MD,…
A fellowship worth more than $1.2 million will fund research focused on improving the mobility of individuals living with Parkinson’s disease. The Advanced Fellowship from the National Institute for Health and Care Research was awarded to Rosie Morris, PhD, director of the Physiotherapy Innovation Laboratory at Northumbria University, in…
Get regular updates to your inbox.
